【摘要】：目的：（1）研究對(duì)象隨機(jī)分為鹽酸阿米洛利組(治療組)及基礎(chǔ)治療組（對(duì)照組），探討阿米洛利對(duì)不同程度急性腦梗死患者神經(jīng)功能缺損程度的影響。（2）檢測(cè)兩組患者不同時(shí)期血清Glu、TGF-β1的水平，結(jié)合阿米洛利的作用機(jī)制探討阿米洛利在腦梗死發(fā)生發(fā)展中的作用。 方法：將60例急性腦梗死患者隨機(jī)分為治療組(鹽酸阿米洛利片2.5mg次，，1次日，晨起口服)和對(duì)照組，兩組均給予基礎(chǔ)及對(duì)癥治療，持續(xù)用藥14天，于入院當(dāng)天、入院后第14天采用酶聯(lián)免疫吸附法（ELISA）分別測(cè)定2組患者血清Glu、TGF-β1的水平,同時(shí)對(duì)其神經(jīng)功能缺損程度進(jìn)行評(píng)分，另對(duì)入院時(shí)所有患者血清Glu、TGF-β1水平進(jìn)行兩變量相關(guān)性分析。數(shù)據(jù)采用SPSS16.0進(jìn)行統(tǒng)計(jì)分析，P0.05差異有統(tǒng)計(jì)學(xué)意義。 結(jié)果：治療前，2組患者神經(jīng)功能缺損程度NIHSS評(píng)分、血清Glu及TGF-β1含量的差異無(wú)統(tǒng)計(jì)學(xué)意義(P＞0.05)。治療后各項(xiàng)試驗(yàn)室指標(biāo)較治療前有明顯改善。治療后對(duì)照組及治療組的神經(jīng)功能缺損評(píng)分分別為{(9.00±4.35)vs(8.10±3.89)}分，兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P＞0.05)；治療后對(duì)照組及治療組的血清Glu水平分別為{(64.77±14.60) vs(57.36±13.42)}μmol/L，兩組比較差異有統(tǒng)計(jì)學(xué)意義(P＜0.05)；治療后對(duì)照組及治療組的血清TGF-β1水平分別為{(26.36±6.06)vs(34.81±7.36)}pg/ml，兩組比較差異有統(tǒng)計(jì)學(xué)意義(P＜0.05)；治療前對(duì)所有患者血清Glu與TGF-β1含量做線性相關(guān)分析，結(jié)果顯示二者呈負(fù)相關(guān)（r=-0.230），Y=42.979-0.23X。即急性腦梗死患者血清TGF-β1含量隨Glu的增多呈下降趨勢(shì)（P＜0.05）。 結(jié)論：（1）阿米洛利組與基礎(chǔ)治療組患者的神經(jīng)功能缺損程度評(píng)分（NIHSS評(píng)分）較治療前有降低。（2）治療后兩組患者血清Glu水平較治療前均顯著降低，但治療組較對(duì)照組降低明顯。（3）兩組患者血清TGF-β1水平較治療前顯著增高，但治療組較對(duì)照組增高明顯。（4）急性腦梗死患者血清TGF-β1含量隨Glu的增多呈下降趨勢(shì)，兩者呈負(fù)相關(guān)。阿米洛利對(duì)急性腦梗死患者的預(yù)后有一定的改善作用。
[Abstract]:Objective: (1) the subjects were randomly divided into two groups: amiolol hydrochloride group (treatment group) and basic treatment group (control group). To investigate the effect of amilolol on the degree of neurological deficit in patients with acute cerebral infarction. (2) to detect the level of serum Glu,TGF- 尾 1 in two groups of patients at different stages. To explore the role of amiloride in the occurrence and development of cerebral infarction combined with the mechanism of amiloride. Methods: sixty patients with acute cerebral infarction were randomly divided into two groups: treatment group (2.5mg group) and control group. Both groups were given basic and symptomatic treatment for 14 days. On the 14th day after admission, the level of serum Glu,TGF- 尾 1 was measured by enzyme linked immunosorbent assay (ELISA) in both groups, and the degree of neurological impairment was evaluated. The serum Glu, of all patients was also evaluated on admission. TGF- 尾 1 level was analyzed by two variable correlation analysis. Data using SPSS16.0 statistical analysis, P0.05 differences were statistically significant. Results: there was no significant difference in NIHSS score, serum Glu and TGF- 尾 1 levels between the two groups before treatment (P > 0. 05). After treatment, the laboratory indexes were significantly improved compared with those before treatment. After treatment, the neurological impairment scores of the control group and the treatment group were (9.00 鹵4.35) vs (, 8.10 鹵3.89)}, respectively. There was no significant difference between the two groups (P > 0. 05). After treatment, the serum Glu levels of the control group and the treatment group were (64.77 鹵14.60) vs (鹵57.36 鹵13.42)} 渭 mol/L, respectively. The serum TGF- 尾 1 levels in the control group and the treatment group were (26.36 鹵6.06) vs (34.81 鹵7.36)} pg/ml, respectively. The serum Glu and TGF- 尾 1 levels in all patients were analyzed by linear correlation analysis before treatment. The results showed that there was a negative correlation between the two levels (r-0.230) and YT 42.979-0.23X. That is, serum TGF- 尾 1 content decreased with the increase of Glu in patients with acute cerebral infarction (P < 0. 05). Conclusion: (1) the NIHSS score of patients in amilolol group and basic treatment group was lower than that before treatment. (2) after treatment, the serum Glu level in both groups was significantly lower than that before treatment. But the serum TGF- 尾 1 level in the treatment group was significantly lower than that in the control group. (3) the serum TGF- 尾 1 level in the two groups was significantly higher than that in the control group, but the serum TGF- 尾 1 level in the treatment group was significantly higher than that in the control group. (4) the serum TGF- 尾 1 level in the patients with acute cerebral infarction decreased with the increase of Glu. There was a negative correlation between the two. Amiloride can improve the prognosis of patients with acute cerebral infarction.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R743.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 楊梅;胡治平;;TGF-β_1、Caspase-3與腦損傷缺血再灌注的相互關(guān)系[J];醫(yī)學(xué)臨床研究;2006年02期

2 張三妹;李光來(lái);;阿米洛利對(duì)大鼠腦缺血再灌注損傷后線粒體SDH的影響[J];臨床醫(yī)藥實(shí)踐雜志;2008年01期

3 莊稼英;;2012年ADA糖尿病診療指南(一)[J];糖尿病天地(臨床);2012年02期

4 ;北滿特殊鋼集團(tuán)有限責(zé)任公司[J];特殊鋼;2003年05期

5 張中興,盧紅,張萍,宋景貴,張帆,劉麥仙;腦梗死后血、腦脊液中興奮性氨基酸變化與神經(jīng)功能缺失的關(guān)系[J];中國(guó)臨床康復(fù);2003年25期

6 ;腦卒中患者臨床神經(jīng)功能缺損程度評(píng)分標(biāo)準(zhǔn)（1995）[J];中華神經(jīng)科雜志;1996年06期

7 張三妹;李光來(lái);;阿米洛利對(duì)大鼠腦缺血再灌注損傷后ATP酶的影響[J];中西醫(yī)結(jié)合心腦血管病雜志;2008年02期

本文編號(hào)：2417033